Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28757603 | 1.00 | TSHR (0.52) | TSHRLMNAALDH1A1TDP1KDM4E | |
| SCHEMBL3642758 | 0.80 | TSHR (0.61) | TSHRLMNAALDH1A1TDP1ACP3 | |
| SCHEMBL8870718 | 0.80 | KMT2A (0.54) | TSHRLMNAALDH1A1TDP1KDM4E | |
| SCHEMBL741878 | 0.80 | TSHR (0.52) | TSHRLMNAALDH1A1KDM4EACP3 | |
| SCHEMBL3845818 | 0.80 | KMT2A (0.54) | TSHRLMNAALDH1A1TDP1KDM4E | |
| SCHEMBL12395375 | 0.80 | TSHR (0.52) | TSHRLMNAALDH1A1TDP1KDM4E | |
| SCHEMBL7734153 | 0.80 | TSHR (0.52) | TSHRLMNAALDH1A1TDP1KDM4E | |
| SCHEMBL11797282 | 0.78 | TSHR (0.53) | TSHRLMNAALDH1A1TDP1ACP3 | |
| SCHEMBL7295540 | 0.78 | TSHR (0.48) | TSHRLMNAALDH1A1TDP1KDM4E | |
| SCHEMBL11707796 | 0.77 | TSHR (0.57) | TSHRLMNAALDH1A1TDP1ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1863774-B | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2010-12-15 | — | — | CN | disclosed |
| CN-1863774-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-11-15 | — | — | CN | disclosed |
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-7049444-B2 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| CN-1192021-C | 3-azabicyclo [3.1.0] hexane derivatives as opioid receptor ligands | PFIZER LTD (US) | 2005-03-09 | — | — | CN | disclosed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | disclosed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| CN-1331679-A | 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands | PFIZER LTD (US) | 2002-01-16 | — | — | CN | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| US-4459296-A | HYPOTENSIVE | DELALANDE S.A. (FR) | 1984-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | TSHR 3143/4885LMNA 3931/4885ALDH1A1 70/4885 |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | TSHR 3143/4885LMNA 3931/4885ALDH1A1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.